Eluciderm, Inc.
PrivateLast Round
VC Round
Jun 18, 2024
Total Funding Raised
$375,000
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Eluciderm, Inc. is a biotechnology company that develops topically administered small-molecule drugs intended to facilitate scarless wound healing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Eluciderm, Inc. Comparables
Compare Eluciderm, Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PolarityBio, Inc. | 81% | |
| Healiva SA | 79% | |
| Omeza | 79% | |
Eluciderm, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jun 18, 2024 | ||||
| VC Round | Apr 22, 2022 | ||||
| Seed | Oct 4, 2021 |
Key People
Founding team and executive leadership
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 20, 2026
Presented a poster at the 2026 Symposium on Advanced Wound Care.
- Apr 20, 2026
Won second international wound healing award for product ELU42.
Eluciderm, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Eluciderm, Inc.'s valuation, stock price, and market status.